Suvratoxumab

Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.

Suvratoxumab
Monoclonal antibody
Type?
SourceHuman
TargetStaphylococcus aureus alpha toxin
Clinical data
Other namesMEDI4893
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6556H10114N1730O2100S44
Molar mass148179.68 g·mol−1

This drug was developed by MedImmune[2]

References
  1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.